In vitro diagnostics are tests that diagnose and prevent diseases, conditions or infections. IVD tests are performed outside body in an artificial environment on samples such as blood, urine, tissue isolated from human body. IVD is classified into 3 types namely: clinical laboratory testing, near-patient testing, self-testing. IVD market is segmented by-techniques (including immunoassays, point of care, molecular diagnostics, hematology, coagulation, microbiology, clinical techniques, microbiology), product-type (including instruments, reagents, services, data management systems), usability (including disposable, reusable), applications (including diabetes, oncology, cardiology, HIV/AIDS, autoimmune disease, nephrology, drug testing), -end-user (including hospitals, laboratories, academics) and geography (globally).
The Global IVD Market was reported with high revenue in previous years and hence expected to grow at a high CAGR by 2019. The Asia-Pacific and RoW regions are expected to register a significant growth rate for the IVD market. North America commands the largest share while Asia Pacific is the fastest revenue growing region.
IVD market growth is driven by factors such as increase in incidences of chronic and infectious diseases across all age cohorts, genetic diseases, aging population, rising acceptance of personalized medicine, rise in healthcare awareness in patients and high unmet medical needs in diagnosing diseases. Screening initiatives and high investment in healthcare infrastructures mainly contributes to market growth. Whereas, difficulty in rendering rapid diagnostic results, stringent regulatory policies, reimbursement issues and economic crisis are the major growth restraints. Different geographies is an opportunistic factor which improved IVD market growth.
Roche diagnostics (Basel, Switzerland) is expected to be the largest player in the IVD market, followed by Siemens and Abbott. The IVD market is highly consolidated, with the major players holding close to 80% market share. Top ten major players are Roche Diagnostics, Siemens Healthcare(Erlangen, Germany), Abbott(Abbott Park, Illinois), Johnson and Johnson(New Jersey), Beckman Coulter(Massachusetts), Becton Dickinson(U.S.), bioMerieux (France), Bayer Diabetes(Germany), Sysmex (U.S.) and Bio-Rad(California). Key players such as Thermo Fisher Scientific, Inc., QIAGEN N.V., and ARKRAY, Inc. have established new manufacturing facilities and R&D units in China to grow IVD market.
The focus of this research report description was on various levels of analysis, industry, market shares, value chain, PESTEL analysis and company profiles which together comprise and augment about competitive landscape, emerging and high growth segments of in vitro diagnostic (molecular diagnostics & point of care testing), emerging technologies.
The report provides an in depth market analysis of the above mentioned segments across the following regions:
• North America
• Rest of the World (RoW)
Table Of Contents
- Executive Summary.
2.1. Key Take Aways.
2.2. Report Description.
2.3. Markets Covered.
2.5. Research Methodology.
2.5.1. Market Size Estimation.
2.5.2. Market Breakdown And Data Triangulation.
2.5.3. Key Data Points From Secondary Sources.
2.5.4. Key Data Points From Primary Sources.
- Market Analysis.
3.2. Market Segmentation.
3.3. Factors Influencing Market.
3.3.1. Drivers And Opportunities.
188.8.131.52. Aged Cohort With Increased Incidence Of Chronic And Infectious Diseases And Implementation Of Minimal Invasive Technology.
184.108.40.206. Point-Of-Care Testing (Poct) And Its Technological Advancements.
220.127.116.11. Prevalence Of Personalized Medicine Approach.
18.104.22.168. Healthcare Awareness And Government Funding.
22.214.171.124. Extending Reach Of Molecular Diagnostics.
126.96.36.199. Commercial Trends For Development Of Condition-Specific Markers In Ivd Tests.
188.8.131.52. Biothreat Warfare Agents Posing An Opportunity.
3.3.2. Restraints And Threats.
184.108.40.206. Affordability Of Healthcare Diagnostics.
220.127.116.11. Intensified Competition.
18.104.22.168. Reimbursement Issues.
22.214.171.124. Stringent Regulatory Framework:.
126.96.36.199. Medical Device Excise Tax:.
3.3.3. Problem Areas.
188.8.131.52. Laboratory Automation For Increased Efficiency And Accurate Diagnosis:.
3.3.4. Winning Imperative.
184.108.40.206. Non-Proprietary System With Enhanced Functionalities.
For more information or any query mail at firstname.lastname@example.org
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym